Appili Therapeutics Inc has seen significant price movement recently, with notable developments in its operational landscape.
This week, Appili Therapeutics Inc (APLI.TO) continues to attract attention as its stock price reflects a notable decline. Investors are keen to understand the factors influencing this trend, particularly in light of recent company announcements and financial results.
Investor takeaway: Appili's recent financial disclosures and the announcement of an acquisition agreement highlight potential growth avenues, but the stock's current performance raises questions about its immediate viability.
Advertisement
Appili Therapeutics Inc
APLI.TO
APLI.TO
Appili Therapeutics Inc
WealthAwesomeMarket cap
$1.99M
52W high
$0.04
52W low
$0.01
1W change
+50.00%
Beta
-0.20
Analyst Price Targets
Based on analyst covering APLI
Wall Street analysts forecast APLI stock price to rise 900.0% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$0.15
+900.0% Upside
Current Price
C$0.01
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on APLI's historical volatility
30-Day Vol
292.8%
Annualized
90-Day Vol
261.7%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$0.01
Expected price
| Horizon | Expected | 68% Range (1ฯ) |
|---|---|---|
| 30 trading days | C$0.01 | C$0.01 โ C$0.04 |
| 60 trading days | C$0.01 | C$0.00 โ C$0.06 |
| 90 trading days | C$0.01 | C$0.00 โ C$0.07 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ยฑ1ฯ, 95% band = ยฑ2ฯ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Appili's stock has dropped 60% year-to-date.
The stock's current price is at the lower end of its 52-week range, suggesting significant volatility and investor uncertainty.
Bull case
The recent US$40 million award for VXV-01 and a definitive acquisition agreement with Aditxt could provide substantial financial support and strategic advantages for Appili moving forward. These developments may open new opportunities for growth and enhance the company's market position.
Bear case
Despite these positive developments, the stock has experienced a dramatic drop in price, indicating potential underlying challenges that may affect investor confidence. The significant decline raises concerns about the company's short-term viability and its ability to recover in the current market.
Recent Price Action
Appili Therapeutics Inc (APLI.TO) closed at C$0.01, unchanged from the previous day. Over the past week, the stock has dropped by 33.33%, and it has seen a significant decline of 60% year-to-date. The recent trading volume reached 239,050 shares, which is notably higher than the 20-day average volume of 52,139 shares, indicating heightened trading activity.
Catalysts Behind the Movement
Advertisement
While there has been no major news this week, Appili Therapeutics has recently reported its fiscal year 2026 financial and operational results. The company highlighted advancements in its commercial-stage programs and the securing of a US$40 million award for its VXV-01 program. Additionally, the announcement of a definitive agreement with Aditxt to acquire Appili may influence investor sentiment positively. However, the lack of immediate positive price action following these announcements suggests that investors are weighing these developments against the backdrop of the stock's recent performance.
Technical Picture
From a technical standpoint, Appili's stock is currently trading at the lower end of its 52-week range of C$0.01 to C$0.04. The stock is significantly below both its 50-day moving average (C$0.02) and 200-day moving average (C$0.02), indicating a bearish trend. The beta of -0.21 suggests that the stock is less volatile than the market, but the current performance raises concerns about its stability.
Insider Activity
No insider activity has been reported for Appili Therapeutics Inc this week, which may indicate a period of observation as investors await further developments.
Price Action Summary
As it stands, Appili Therapeutics Inc closed at C$0.01, reflecting a 1-day change of 0.00%. The stock's recent performance has raised significant questions among investors, particularly in light of its year-to-date decline.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile โโ Reviewed by Certified Financial Professionals
This content has been reviewed by CFAยฎ charterholders and Certified Financial Planners (CFPยฎ) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFAยฎ charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFPยฎ professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
โ ๏ธ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
